Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19814829 | 1.00 | DPP4 (0.44) | DPP4ACKR3SMN1; SMN2POLBSLC6A2 | |
| SCHEMBL19816437 | 0.98 | DPP4 (0.42) | DPP4ACKR3SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL29775816 | 0.98 | DPP4 (0.42) | DPP4ACKR3SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL19814563 | 0.81 | DPP4 (0.45) | DPP4ACKR3SMN1; SMN2POLBKDM2B | |
| SCHEMBL28331059 | 0.81 | DPP4 (0.45) | DPP4ACKR3SMN1; SMN2POLBKDM2B | |
| SCHEMBL19616801 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBKDM2BHSD17B10 | |
| SCHEMBL19814406 | 0.79 | DPP4 (0.44) | DPP4ACKR3KDM2B | |
| SCHEMBL28332554 | 0.79 | DPP4 (0.44) | DPP4ACKR3KDM2B | |
| SCHEMBL29775873 | 0.78 | ACKR3 (0.37) | ACKR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19815189 | 0.78 | ACKR3 (0.37) | ACKR3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | DPP4 2777/4885ACKR3 3/4885SMN1; SMN2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.